Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

05 March 2020

Inside the race to find a coronavirus vaccine

Writing for Devex, Jenny Lei Ravelo looks at how the global health community is trying to fast-track the development of a vaccine against the novel coronavirus. Alex Kong, researcher for the Access to Medicine Index, is quoted in the article on the potential access barriers in the face of a global outbreak.

Direct links

Read the full article

The article dives into some of the factors that may affect global access to the vaccine, once a viable candidate has been developed. Alex Kong explains that companies who are exploring medicines that can be repurposed for COVID-19 can be a positive thing "as governments are also more likely to allow trials for medicines already in use or under investigation." Alex also talks about some of the potential hurdles to consider early on such as supply shortages and stockouts - especially for low- and middle-income countries. 

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved